Akèy › Skleroderm Difize › Kansas
Etid klinik pou Skleroderm Difize nan Kansas
5 etid pou Skleroderm Difize ap chèche patisipan nan sit nan Kansas.
Vil nan Kansas
Tèks ofisyèl etid la (Anglè)
EncompaSSc: Evaluation of MTX-474 in Participants With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
- EncompaSSc site in Kansas City, KS, Kansas City
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 15, 2026 · NCT07287670A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
- University of Kansas Medical Center, Kansas City
Ap rekriteFaz 1
Laj 18 a 74 · Tout sèks · Mizajou Sep 10, 2026 · NCT07085104Platform Clinical Study for Conquering Scleroderma
- University of Kansas School of Medicine, Kansas City
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Aug 18, 2026 · NCT06195072RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis
- University of Kansas Medical Center, Kansas City
Ap rekriteFaz 2/3
Laj 18 a 75 · Tout sèks · Mizajou Aug 17, 2026 · NCT06328777A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)
- Nkarta Investigational Site, Fairway
Ap rekriteFaz 1/2
Laj 18 a 75 · Tout sèks · Mizajou Aug 7, 2026 · NCT06733935Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.